Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker

A kit and prognostic technology, applied in the kit for predicting the prognosis of NSCLC patients and the application field of osteopontin as a specific marker, can solve problems such as poor prognosis, achieve simple methods, improve long-term survival rate, improve prognostic effect

Inactive Publication Date: 2014-07-16
TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Further analysis showed that patients with OPN-positive TAMs infiltration were more likely to develop distant metastasis and had a worse prognosis than patients with OPN-negative TAMs infiltration
This has never been reported in previous studies on NSCLC

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker
  • Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker
  • Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] A kit for predicting the prognosis of NSCLC patients is characterized by comprising CD68 monoclonal antibody, OPN monoclonal antibody, fluorescent secondary antibody and immunofluorescence reagent.

[0088] The method of using the above kit to predict the prognosis of NSCLC cancer patients and guide zoledronic acid is as follows:

[0089] 1. Select NSCLC patients who need to be predicted, find their paraffin-embedded tissue blocks from the specimen bank, and parallel tissue sections

[0090] 2. Immunofluorescence step

[0091] 1) Tissue sections were routinely dewaxed and hydrated.

[0092] 2) Take out the slices, wash the slices with PBS 3 times, 5 minutes each time.

[0093] 3) High-temperature and high-pressure heat-recovery antigen: 0.01M sodium citrate buffer solution (pH6.0), high-temperature and high-pressure heat-recovery antigen.

[0094] 4) Naturally cool to room temperature.

[0095] 5) Soak the tissue chip in 10% hydrogen peroxide solution in the dark fo...

Embodiment 2

[0110] Select NSCLC patients that need to be predicted, and follow the steps in Example 1. If the results show that there are few OPN-positive macrophages in the tumor stroma, it indicates that these patients have a better prognosis and are less likely to have recurrence and metastasis. Adjuvant therapy should moderate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a kit for constructing forecasting NSCLC (non-small-cell lung cancer) patient prognosis and guiding clinic application of zoledronic acid and application of osteopontin (OPN) acting as a specific marker of M2 type macrophage; the application of the kit provided by the invention is evaluation of the NSCLC patient prognosis by using the expression of OPN in an immunofluorescence double standard technology detection tissue chip in TAMs and tumor cells, and comprehensive measures are taken in real time to interfere aiming at the detection result of the kit, so that the long-term survival rate of patients is increased, and the prognosis is improved; the method is simple and convenient and can be widely applied to clinic.

Description

technical field [0001] The invention relates to the technical field, in particular to a kit for predicting the prognosis of NSCLC patients and the application of osteopontin as a specific marker. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality. Although the comprehensive treatment of lung cancer has made great progress in recent years, its 5-year survival rate is still hovering around 15%. 70% to 80% of lung cancer is non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC), and NSCLC is prone to distant metastasis (brain, bone, adrenal gland and liver metastasis). Even for patients with stage I lung cancer, 27%-55% of patients will have recurrence and metastasis after surgery. How to identify these high-risk groups early and give adjuvant treatment in time is the focus of current research. [0003] At present, factors including microRNAs, genes, chromosomes, and proteins used to predict prognosis or intervene ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/577G01N21/64
CPCG01N33/57423G01N33/533G01N33/68G01N2800/12
Inventor 孙冰生
Owner TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap